| Home | E-Submission | Sitemap | Contact Us |  
J Korean Soc Emerg Med > Volume 33(2); 2022 > Article
Journal of The Korean Society of Emergency Medicine 2022;33(2): 164-171.
코로나19 예방접종센터에서 BNT162b2 mRNA COVID-19 백신 접종 후 발생한 이상반응 환자의 임상 특성
최영환1 , 이강의1 , 조수임1 , 고정인1 , 김연재2 , 최윤영3 , 김건희4,5 , 박태진1
1국립중앙의료원 응급의학과
2국립중앙의료원 감염내과
3국립중앙의료원 소아청소년과
4국립중앙의료원 마취통증의학과
5국립중앙의료원 지역의약품안전센터
BNT162b2 mRNA COVID-19 vaccine adverse reactions needing medical support: a vaccine center experience
Young Hwan Choi1 , Kang Eui Lee1 , Soo Im Cho1 , Jung In Ko1 , Yeon Jae Kim2 , Youn Young Choi3 , Gunn Hee Kim4,5 , Tae Jin Park1
1Department of Emergency Medicine, National Medical Center, Seoul, Korea
2Division of Infection Diseases, National Medical Center, Seoul, Korea
3Department of Pediatrics, National Medical Center, Seoul, Korea
4Department of Anesthesia and Pain Medicine, National Medical Center, Seoul, Korea
5Department of Drug Safety Center, National Medical Center, Seoul, Korea
Correspondence  Tae Jin Park ,Tel: 02-2260-7114, Fax: 02-2279-7075, Email: nmcemergency@gmail.com,
Received: June 15, 2021; Revised: August 20, 2021   Accepted: August 28, 2021.  Published online: April 30, 2022.
The coronavirus disease 2019 (COVID-19) pandemic has not yet been controlled and herd immunity through vaccination against COVID-19 has been considered the best option to prevent the spread of COVID-19 worldwide. We encountered several patients in our emergency department presenting with adverse reactions after COVID-19 vaccinations. Hence, we investigated the clinical characteristics of patients with adverse reactions after vaccination.
In South Korea, 10,510 doses of the BNT162b2 mRNA COVID-19 vaccine was administered to 5,304 medical staff. To investigate adverse reactions, we reviewed the case report forms from the vaccination centers and the medical charts from the date of first dose administration until two weeks after the last planned second dose.
A total of 187 cases, out of the 10,510, experienced adverse reactions and these were more common in females. Dizziness (44.4%), nausea and vomiting (28.3%), and fever (24.1%) were the most reported adverse reactions. Immediate adverse reactions included dizziness, nausea, and vomiting, palpitation, sensory changes, and delayed adverse reactions included fever, myalgia, headache, nausea, and vomiting. The delayed reactions of fever and myalgia were significantly more common after the second, rather than after the first dose (P<0.01 and P=0.03, respectively). One case of anaphylaxis was reported. All adverse reactions improved after conservative care.
Our findings show diverse adverse reactions to the BNT162b2 mRNA COVID-19 vaccine, but none of them required hospitalization. However, since this vaccine has been manufactured using a newly developed technique, more research focused on the clinical significance of the adverse reactions is necessary.
Key words: COVID-19; Vaccination; Adverse reaction; Safety; BNT162b2
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Related article
Editorial Office
The Korean Society of Emergency Medicine
TEL: +82-62-226-1780   FAX: +82-62-224-3501   E-mail: 0012194@csuh.co.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Society of Emergency Medicine.                 Developed in M2PI